Prof Oscar Matzinger
University of Lausanne, Radiation Oncology, Faculty Member
Research Interests:
Research Interests: Evidence Based Medicine, Radiation Therapy, Prostate Cancer, Medicine, Decision Trees, and 13 moreHumans, Consensus, Male, Switzerland, Androgen Deprivation Therapy, Neoplasm Invasiveness, Medicine and Health Sciences, Combined Modality Therapy, Guideline Adherence, Neoplasm grading, Neoplasm staging, Prostatic neoplasms, and Androgen antagonists
Research Interests:
Research Interests:
The European SocieTy for Radiation and Oncology -Advisory Committee on Radiation Oncology Practice (ESTRO-ACROP) endorsed a project to provide guidelines (GL) for the identification and delineation of clinically negative lymph-nodal... more
The European SocieTy for Radiation and Oncology -Advisory Committee on Radiation Oncology Practice (ESTRO-ACROP) endorsed a project to provide guidelines (GL) for the identification and delineation of clinically negative lymph-nodal stations (LNs) involved in upper gastrointestinal clinical scenarios. The presented GL is focused on preoperative (or definitive) setting. The project aim is to improve the consistency of clinical target volume (CTV) delineation by providing: a description of the anatomical boundaries of the LNs; a radiological computed tomography-based atlas depicting the LNs areas; a free, web-based, interactive example case for independent training of radiation oncologists on LNs delineation according to the presented GL, by both qualitative and quantitative analysis (through the FALCON EduCase platform). This project was carried out with the intention to facilitate and improve uniformity of future upper gastrointestinal guidelines on nodal CTV delineation. We report methodology and results from the collaboration of a working group panel selected by the ESTRO-ACROP.
Research Interests:
Research Interests:
Research Interests: Surgery, Medicine, Lung Cancer, Humans, Female, and 15 moreMale, Incidence, Clinical Sciences, Aged, Middle Aged, Adult, Survival Rate, Retrospective Studies, Airway Obstruction, Anastomosis, Postoperative Complications, Bronchopleural fistula, Cardiovascular medicine and haematology, lung neoplasms, and Pneumonectomy
Research Interests:
Research Interests: Surgery, Treatment Outcome, Positron Emission Tomography, Medicine, Humans, and 15 moreFemale, Male, Clinical Sciences, Middle Aged, Neoplasm Invasiveness, Adult, Retrospective Studies, Thymoma, X ray Computed Tomography, Resection, Confluence, Thymectomy, Neoplasm staging, Cardiovascular medicine and haematology, and Pneumonectomy
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests: Radiation, Biology, Cell Cycle, Treatment Outcome, Cancer Research, and 15 moreApoptosis, Medicine, Cell Culture, Biological Sciences, Mitosis, Humans, Physical sciences, Programmed cell death, In Vivo, HeLa cells, HeLa, Radiosensitivity, Radiation Tolerance, Clonogenic Assay, and Medical and Health Sciences
Research Interests: Urology, Brachytherapy, Radiation Therapy, Prostate Cancer, Medicine, and 14 moreHumans, Toxicity, Male, Androgen Deprivation Therapy, Aged, Middle Aged, Intensity Modulated Radiation Therapy, Intensity Modulated Radiotherapy, Acute Toxicity, Urogenital System, Prostatic neoplasms, High risk, Radiotherapy and Oncology, and Urethra
Research Interests: Chemistry, Cancer Research, Apoptosis, Medicine, Signal Transduction, and 15 moreHumans, Female, Animals, Cell Death, Head and neck squamous cell carcinoma, Caspase, In Vivo, Oral Squamous Cell Carcinoma (OSCC), Tumor necrosis factor-alpha, Chemoradiotherapy, Antineoplastic Agents, Mitochondrial Proteins, Inhibitor of apoptosis proteins, Head and neck neoplasms, and Radiotherapy and Oncology
Research Interests:
Research Interests:
Research Interests: Medicine and Gynecology
Research Interests:
Research Interests:
Purpose/objectives: Resistance of tumor cells to chemotherapy (CT) or radiotherapy (RT)-induced apoptosis is a major problem in the treatment of head and neck squamous cell carcinoma (HNSCC), and highlights the need for new therapeutic... more
Purpose/objectives: Resistance of tumor cells to chemotherapy (CT) or radiotherapy (RT)-induced apoptosis is a major problem in the treatment of head and neck squamous cell carcinoma (HNSCC), and highlights the need for new therapeutic strategies. The small molecule Debio 1143 (D1143) (a.k.a. SM-406 or AT-406) is a potent orally-active, monovalent Smac-mimetic designed to promote programmed cell death in tumor cells by blocking the activity of inhibitor of apoptosis proteins (IAPs) to create conditions in which apoptosis can proceed. This study aimed to test the efficacy of D1143 as a single agent and/or in combination with CT or RT in HNSCC models. Materials and methods: The effect of D1143 was assessed by the colony forming assay on a panel of HNSCC patient-derived xenograft (PDX) tumors and established cell lines. Tumor cells were incubated at various concentrations of D1143 (ranging from 0.1 to 30 μM) and treated with increasing doses of radiation or cisplatin. Cells were cultured for a minimum of 10 days before being fixed and stained. The number of surviving colonies was then recorded and compared to an untreated group. In parallel, various treatment sequences were tested, (before, during or post-irradiation) to determine the effect of D1143 on primary apoptosis (early, pre-mitotic apoptosis) and secondary apoptosis (late, post-mitotic reproductive cell death). The in vivo chemo/radiosensitizing effect of oral treatment with D1143 was further evaluated in nude mice bearing HNSCC tumor xenografts. Results: D1143 alone selectively inhibited colony formation of several PDX tumors and established cell lines. In addition, combination experiments found D1143 to be highly effective in enhancing cell death induced by RT or cisplatin. A synergistic effect of D1143 was observed in the majority of the tested cell lines treated by RT, whereas D1143 enhanced the activity of cisplatin in a subset of tumor cells. Interestingly, the radiosensitizing effect of D1143 was preeminent when cells were co-incubated with D1143 24 hours after irradiation, showing that D1143 efficiently impacts late apoptosis due to mitotic catastrophe and/or other cell death events that arise after irradiation. In mice bearing HNSCC radio-resistant tumors, D1143 given orally in combination with RT delayed tumor growth for more than 40 days when compared to RT only and for more than 60 days when compared to vehicle only. In addition, oral administration of D1143 showed additive to synergistic activity when combined with intravenous cisplatin in nude mice bearing PDX HNSCC tumors. Conclusion: Altogether, these results show that D1143 exhibits activity as a single agent and can potentiate the effects of chemo/radiotherapy in HNSCC models indicating that D1143 has a promising therapeutic potential for the treatment of HNSCC. Citation Format: David Viertl, Florence Perillo-Adamer, Stefania Rigotti, Jean-Luc Muralti, Hélène Maby-El Hajjami, Anne Vaslin, Grégoire Vuagniaux, Oscar Matzinger. The SMAC-mimetic Debio 1143 efficiently enhanced chemo and radiotherapy in head and neck squamous cell carcinoma models. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2055. doi:10.1158/1538-7445.AM2013-2055
Research Interests:
Research Interests:
Research Interests:
Irinotecan is a widely used chemotherapeutic agent for colorectal, gastric, lung, and brain cancer. A 41-year-old white man with a history of seasonal rhinitis and heavy smoking presented with headaches and vomiting that had started in... more
Irinotecan is a widely used chemotherapeutic agent for colorectal, gastric, lung, and brain cancer. A 41-year-old white man with a history of seasonal rhinitis and heavy smoking presented with headaches and vomiting that had started in the past 2 weeks. A large bifrontal glioblastoma multiforme was diagnosed. He was started on 14 mg dexamethasone daily and included in a chemotherapy protocol including irinotecan and temozolomide. 125 mg/m 2 oral temozolomide (260 mg/day) was given for 14 days continuously and 350 mg/m 2 irinotecan (750 mg) was administered intravenously on day 7, repeated every 3 weeks. 1 The first two cycles were tolerated well. The dexamethasone dose was tapered to 2 mg per day. 6 days after the third dose of irinotecan, the patient noticed a new dry cough with progressive shortness of breath, eventually requiring admission to hospital on day 12. On admission, the patient had no fever. A tachypnea (24 breaths per min) was present with prolonged expirium, wheezing, and inspiratory crackles at both lung bases. Severe arterial hypoxaemia (PaO2 44 mm Hg, PaCO2 37 mm Hg) was found. A chest radiograph showed bilateral interstitial infiltrates and a high-resolution thoracic CT scan showed a diffuse ground-glass infiltrate of the entire right lung and the left apical lobe, as well as two peripheral foci of alveolar infiltrate (figure 1). The white blood cell count was 8700 cells/L, with 40% segmented neutrophils, 21% bands, 15% lymphocytes, 6% monocytes, and 1% eosinophils. C-reactive protein was 20 mg/L. Other blood chemistry and urinalysis were within normal limits. A bronchofibroscopy showed a normal tracheobronchial tree. Bronchoalveolar lavage fluid showed 0·210 6
Research Interests:
Research Interests:
Research Interests:
The implementation of new techniques of imaging in the daily practice of the radiation oncologist is a major advance in these last 10 years. This allows optimizing the therapeutic intervals and locoregional control of the disease while... more
The implementation of new techniques of imaging in the daily practice of the radiation oncologist is a major advance in these last 10 years. This allows optimizing the therapeutic intervals and locoregional control of the disease while limiting side effects. Among them, positron emission tomography (PET) offers an opportunity to the clinician to obtain data relative to the tumoral biological mechanisms, while benefiting from the morphological images of the computed tomography (CT) scan. Recently hybrid PET/CT has been developed and numerous studies aimed at optimizing its use in the planning, the evaluation of the treatment response and the prognostic value. The choice of the radiotracer (according to the type of cancer and to the studied biological mechanism) and the various methods of tumoral delineation, require a regular update to optimize the practices. We propose throughout this article, an exhaustive review of the published researches (and in process of publication) until December 2011, as user guide of PET/CT in all the aspects of the modern radiotherapy (from the diagnosis to the follow-up): biopsy guiding, optimization of treatment planning and dosimetry, evaluation of tumor response and prognostic value, follow-up and early detection of recurrence versus tumoral necrosis. In a didactic purpose, each of these aspects is approached by primary tumoral location, and illustrated with representative iconographic examples. The current contribution of PET/CT and its perspectives of development are described to offer to the radiation oncologist a clear and up to date reading in this expanding domain.
Research Interests:
Research Interests:
Research Interests:
Research Interests:
The implementation of new techniques of imaging in the daily practice of the radiation oncologist is a major advance in these last 10 years. This allows optimizing the therapeutic intervals and locoregional control of the disease while... more
The implementation of new techniques of imaging in the daily practice of the radiation oncologist is a major advance in these last 10 years. This allows optimizing the therapeutic intervals and locoregional control of the disease while limiting side effects. Among them, positron emission tomography (PET) offers an opportunity to the clinician to obtain data relative to the tumoral biological mechanisms, while benefiting from the morphological images of the computed tomography (CT) scan. Recently hybrid PET/CT has been developed and numerous studies aimed at optimizing its use in the planning, the evaluation of the treatment response and the prognostic value. The choice of the radiotracer (according to the type of cancer and to the studied biological mechanism) and the various methods of tumoral delineation, require a regular update to optimize the practices. We propose throughout this article, an exhaustive review of the published researches (and in process of publication) until December 2011, as user guide of PET/CT in all the aspects of the modern radiotherapy (from the diagnosis to the follow-up): biopsy guiding, optimization of treatment planning and dosimetry, evaluation of tumor response and prognostic value, follow-up and early detection of recurrence versus tumoral necrosis. In a didactic purpose, each of these aspects is approached by primary tumoral location, and illustrated with representative iconographic examples. The current contribution of PET/CT and its perspectives of development are described to offer to the radiation oncologist a clear and up to date reading in this expanding domain.
Research Interests:
Research Interests: Survival Analysis, Treatment Outcome, Radiotherapy, Medicine, Quebec, and 13 moreProspective studies, Humans, Female, Male, Switzerland, Rectal Cancer, Hyperfractionation, Phase II Trial, neoadjuvant therapy, Neoplasm staging, Radiotherapy and Oncology, Preoperative radiotherapy, and Rectal neoplasms
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
La gynecomastie secondaire au traitement par anti-androgenes, est une complication frequente des traitements hormonaux utilises pour les patients souffrant de cancer prostatique. Cette gynecomastie est le resultat d'un desequilibre... more
La gynecomastie secondaire au traitement par anti-androgenes, est une complication frequente des traitements hormonaux utilises pour les patients souffrant de cancer prostatique. Cette gynecomastie est le resultat d'un desequilibre hormonal entre les oestrogenes et les androgenes. On peut raisonnablement estimer que l'incidence de cette gynecomastie va augmenter compte tenu de l'effet benefique de la manipulation hormonale sur le devenir des patients atteints d'un cancer de la prostate. La gynecomastie, souvent associee a la mastodynie, a un effet deletere sur la qualite de vie. Si la chirurgie est une option therapeutique pour les formes installees et irreversible, caracterisee par une composante de hyalinisation et fibrose dominant le tableau histologique, la radiotherapie reste le traitement de choix pour les formes precoces, voire meme a titre prophylactique dans les groupes de patients a haut risque. C'est un traitement simple et efficace, peu toxique et benefique en qualite de vie et ceci a ete confirme par des essais randomises. L'approche medicamenteuse n'a pas encore demontre son efficacite ni son innocuite et de toute facon aucune substance medicamenteuse n'a ete enregistree pour cette indication.
Research Interests:
Research Interests:
Research Interests:
15098 Background: To report a single-center experience treating patients with squamous-cell carcinoma of the anal canal using helical tomotherapy (HT) and concurrent chemotherapy, and compare the dosimetric results with 3D conformal... more
15098 Background: To report a single-center experience treating patients with squamous-cell carcinoma of the anal canal using helical tomotherapy (HT) and concurrent chemotherapy, and compare the dosimetric results with 3D conformal radiotherapy (RT) or intensity modulated RT (IMRT). Methods: From May 2007 to December 2007, 8 patients were treated with HT and concurrent chemotherapy (5-fluorouracil and mitomycin) for anal squamous-cell carcinoma. All patients underwent computed-tomography-based treatment planning, with pelvic regions and inguinal nodes receiving 36 Gy in 1.8 Gy per fraction. Following a planned one-week break, primary tumor site and involved nodes were boosted to a total dose of 59.4 Gy. DVHs of several organs at risk (OAR; bladder, small intestin, rectum, femoral heads, penile bulb, external genitalia) were assessed in terms of conformal avoidance. All toxicity was scored according to the Common Terminology Criteria for Adverse Events, version 3.0. HT plans and treatment were implemented...